Princeton, New Jersey is part of one of the most active pharmaceutical and biotechnology environments in the United States. Research teams here work across therapeutic discovery, biologics development, translational research, bioanalysis, and preclinical programs that depend on highly specific antibody reagents.
At Precision Antibody, we support Princeton pharmaceutical and biotechnology teams with custom antibody development programs designed around the intended scientific application.
That distinction matters.
Generating an antibody that binds an antigen is only one part of a successful development program. For many pharmaceutical applications, the antibody must perform under specific assay conditions, distinguish between closely related molecular states, maintain suitable affinity and binding kinetics, work within biological matrices, or function as part of a carefully selected antibody pair.
Our development philosophy is built around those requirements from the beginning.
Precision Antibody was founded in 2000 and has completed several thousand customized antibody projects for pharmaceutical, biotechnology, diagnostic, academic, and government research organizations. Our antibody development work is performed at our facility in Columbia, Maryland, allowing us to serve Princeton and central New Jersey teams through a specialized USA based development operation without implying a physical laboratory presence in Princeton.
For organizations searching for custom antibody development in Princeton, NJ, our focus is straightforward: understand what the antibody needs to accomplish, design the development program around that goal, generate suitable candidates, and provide the data needed to make informed decisions throughout the project.
Precision Antibody was founded by scientists, run by scientists, and created for scientists. We are experts in antibody development, but what makes us different from all the other antibody development experts out there?
Precision Antibody’s founder Dr. Jun Hayashi is an accomplished Developmental Immunologist who has established the antibody development platform unique to the company. Dr. Ginette Serrero, CEO is a Cancer Biologist with expertise in Biochemistry and target discovery which add basic understanding and solving of biological questions to the antibody development strategy.
Dr. Ginette Serrero, CEO is a Cancer Biologist with expertise in Biochemistry and target discovery which add basic understanding and solving of biological questions to the antibody development strategy. They have been working together and have had long and successful careers in Academia and Industry.
They lead Precision Antibody with a core team of Ph.Ds. with expertise in Immunology, Cancer Biology, Biochemistry, Molecular & Cell Biology, and Developmental Biology. Our team’s wide range of skills and knowledge allows us to understand your goal in the global biology context and enable us to provide professional guidance in designing and implementing a perfect project to successfully develop antibodies that will meet customer’s expectations.
Custom antibody development can support many stages of pharmaceutical research, but the requirements can vary substantially from one program to another.
A research antibody used for target detection does not necessarily require the same characteristics as an antibody used in a pharmacokinetic assay. Likewise, an anti-idiotype antibody designed to recognize a therapeutic monoclonal antibody may need different binding behavior depending on whether the assay is intended to measure free drug, total drug, or another defined molecular population.
That is why our project discussions begin with the intended application.
Before beginning development, we work to understand the scientific objective of the program.
Important questions may include:
What molecule or epitope must the antibody recognize?
What assay or biological application will the antibody support?
Does the antibody need to distinguish between free and target bound therapeutic antibody?
Will the antibody be used in serum, plasma, or another biological matrix?
Does the project require a capture and detection pair?
Are affinity, off-rate, or binding kinetics important to downstream performance?
Will candidate antibodies require additional characterization, sequencing, production, or cell line development?
These questions help shape immunogen strategy, screening conditions, characterization, and candidate selection.
Our goal is not simply to identify positive clones. We focus on identifying clones that demonstrate the characteristics needed for the intended application.
That application-specific approach is particularly valuable for pharmaceutical teams working under defined assay requirements, development timelines, and program milestones.
Princeton sits within a broader central New Jersey life sciences environment that includes pharmaceutical research, biotechnology companies, academic research, therapeutic development programs, and emerging life sciences ventures.
Precision Antibody supports organizations in this environment from our Columbia, Maryland development facility.
For Princeton teams, this means access to specialized antibody development capabilities without needing to limit vendor selection to providers physically located within New Jersey.
Our work can support organizations developing:
• Therapeutic monoclonal antibodies
• Bioanalytical assays
• Pharmacokinetic assays
• Immunogenicity programs
• Research reagents
• Diagnostic antibody tools
• Fully human antibody candidates
• Custom anti-idiotype reagents
• Antibody characterization workflows
The scientific requirements of each project determine the development approach.
Anti-idiotype antibody development is one of the most specialized areas of our work.
Anti-idiotype antibodies recognize unique structural features associated with another antibody. In pharmaceutical development, they are often generated against therapeutic monoclonal antibodies and used as highly specific reagents in pharmacokinetic, bioanalytical, and related assay workflows.
Precision Antibody has completed more than 200 anti-idiotype projects. We use application-specific screening and characterization to identify antibodies suited to the scientific requirements of each program.
Teams that need deeper information about our workflow can review our custom anti-idiotype antibody development capabilities, including development phases, screening considerations, antibody pairing, and characterization.
Not every anti-idiotype antibody behaves in the same way.
The location of the recognized epitope can influence whether an anti-ID reagent binds the therapeutic antibody when its target antigen is present.
For that reason, understanding the distinction between anti-paratope and anti-idiotope antibodies can be important when designing a PK or bioanalytical assay.
An anti-paratope antibody recognizes the antigen binding region of the therapeutic antibody.
Because the therapeutic antibody’s target antigen may occupy or alter access to that region, anti-paratope binding can depend on whether the drug antibody is free or target bound.
This behavior can make anti-paratope antibodies useful when an assay needs to measure free therapeutic antibody rather than all circulating forms.
The exact assay architecture still matters. Antibody selection should therefore be based on the specific measurement objective, biological matrix, therapeutic molecule, and assay format.
Anti-idiotope antibodies can recognize unique features outside the immediate antigen binding site.
Depending on the location of the recognized idiotope and the assay design, these antibodies may continue to recognize a therapeutic antibody even when the drug is bound to its antigen.
That can make them useful in assay strategies where detecting a broader population of therapeutic antibody is important.
The appropriate choice depends on what the bioanalytical team needs to measure.
Rather than assuming one anti-ID format is universally preferable, our development process focuses on the intended assay behavior.
Many PK immunoassays rely on a compatible capture and detection antibody pair.
Identifying two antibodies that bind the therapeutic molecule independently can be more demanding than identifying individual positive clones.
A pair must perform together.
Factors may include:
• Epitope compatibility
• Relative affinity
• Binding kinetics
• Assay orientation
• Signal strength
• Background
• Matrix behavior
• Interference from therapeutic target molecules
Precision Antibody can evaluate candidate relationships and support antibody pairing as part of anti-idiotype development.
Epitope binning using technologies such as Octet can help determine whether antibodies recognize distinct or overlapping binding regions. These data can support rational pair selection instead of relying only on trial and error.
An antibody can perform well in a simplified screening environment and behave differently in serum or another complex biological matrix.
This is one reason application-specific screening is important.
Matrix effects can result from nonspecific interactions, endogenous immunoglobulins, serum proteins, target molecules, or other components that alter signal, background, or binding behavior.
For PK assay development, these effects may directly influence whether a reagent is practical.
Our anti-ID development approach can incorporate relevant screening conditions so candidate selection reflects the environment in which the antibodies are expected to function.
The objective is to identify antibodies that are not only antigen positive, but useful within the intended analytical system.
Binding strength alone does not fully describe antibody performance.
Affinity and kinetic behavior can both influence how an antibody functions within a particular assay or workflow.
For selected candidates, characterization may include technologies such as Octet and Biacore to examine binding properties.
These tools can provide insight into:
• Affinity
• Association behavior
• Dissociation behavior
• Relative off-rate
• Epitope relationships
• Candidate comparability
A slower dissociation rate may be advantageous in some assay designs, while another project may prioritize a different combination of characteristics.
The goal is not to pursue the highest numerical affinity without context. The goal is to understand which candidate characteristics best support the intended application.
Precision Antibody also supports fully human monoclonal antibody development for therapeutic research programs.
Fully human antibodies can be valuable when teams want antibody candidates that contain human immunoglobulin sequences from the beginning of the discovery process.
Our fully human antibody development capability uses Trans Chromosomics mice designed to generate antigen-specific fully human IgG antibodies.
Transgenic mouse technologies allow researchers to combine an intact immune response with human immunoglobulin sequence generation.
Following immunization with the selected target, antigen-specific B cells can generate fully human antibody candidates that have undergone immune selection and maturation in vivo.
This provides a route to fully human monoclonal antibodies without beginning with a conventional mouse antibody that later requires humanization.
For therapeutic discovery teams, this can simplify certain downstream development considerations and create a more direct path to evaluating human antibody candidates.
The appropriate strategy still depends on the target, therapeutic objective, desired antibody properties, and development stage.
A fully human antibody program requires more than immunization.
The development process generally involves several scientific stages, each of which contributes to candidate quality.
A program may include:
Review of the target and intended application
Immunogen strategy
Immunization and immune response monitoring
Fusion and hybridoma generation
Primary screening
Application-specific secondary screening
Clone selection
Characterization
Sequencing or production support when required
By defining the intended function early, screening can be designed to identify candidates with characteristics that matter to the therapeutic research program.
The value of an antibody candidate often extends beyond the original screening campaign.
Depending on project requirements, downstream work may include:
• Variable region sequencing
• Antibody production
• Purification
• Binding characterization
• Cell line development
• Candidate comparison
• Functional testing
• Anti-idiotype reagent development
This continuity can be particularly useful as therapeutic antibody programs progress.
A team developing a fully human monoclonal antibody may later need anti-ID reagents to support PK studies, bioanalysis, or other preclinical development activities. Having both capabilities within the broader Precision Antibody service offering can help maintain scientific continuity across different phases of a program.
Custom antibody projects involve uncertainty.
Biology does not always follow a predictable schedule, and a positive antibody response does not guarantee that the resulting reagent will meet the final application requirements.
Our project structure is designed to make that uncertainty more manageable.
Development begins with scientific planning.
The quality and relevance of the immunogen can influence the antibodies produced, so antigen strategy should be considered in relation to the desired antibody function.
For anti-idiotype programs, that may involve understanding the therapeutic antibody, target interactions, intended measurement strategy, and required assay behavior.
For fully human antibody development, the target and therapeutic objective help guide immunization and screening decisions.
Early planning can reduce the likelihood of pursuing candidates that are biologically interesting but unsuitable for the intended application.
Following a successful immune response, hybridoma generation and cloning create individual antibody producing candidates.
The critical step is how those candidates are evaluated.
A basic binding assay may identify antibodies that recognize the target, but pharmaceutical development often requires additional screening criteria.
Application-specific screening can help evaluate whether antibodies perform under conditions more representative of their intended use.
That may include:
• Competitive binding conditions
• Therapeutic target presence
• Serum or biological matrix conditions
• Pairing experiments
• Functional assay formats
• Relevant specificity testing
The exact screening design should follow the project objective.
Once promising clones have been identified, further characterization can help differentiate among candidates.
Characterization may evaluate binding properties, kinetics, epitope relationships, functional activity, or other project-specific criteria.
Octet and Biacore technologies can support quantitative evaluation of antibody interactions when those measurements are relevant to the program.
This allows candidate selection to be based on a broader scientific profile rather than a single positive screening result.
Precision Antibody structures development work around project phases and milestones.
This provides customers with opportunities to review results as the program progresses rather than committing blindly to the entire process without visibility.
Milestone-based development can help teams:
Review immune response before advancing.
Assess fusion and screening data.
Compare candidate clones.
Determine whether additional characterization is justified.
Select antibodies based on application requirements.
Plan production or downstream work based on actual results.
Customers retain ownership of developed clones according to the applicable project terms, and confidentiality arrangements can be established for proprietary research programs.
For pharmaceutical and biotechnology teams, those considerations are often just as important as the underlying antibody science.
A Princeton organization evaluating custom antibody providers may have access to many large CROs and broad life sciences service companies.
Our value lies in specialization.
We have spent more than two decades focusing on antibody development, screening, characterization, and related services.
Precision Antibody was founded in 2000.
Since then, we have completed several thousand customized antibody projects across pharmaceutical, biotechnology, diagnostic, academic, and government research environments.
That experience matters because antibody development programs can differ significantly in target biology, assay requirements, immunogenicity, screening behavior, and downstream expectations.
There is no single protocol that fits every project.
Experience helps inform which questions need to be asked early and which screening decisions may affect later performance.
Timelines matter in pharmaceutical research.
A delayed critical reagent can affect assay validation, preclinical studies, program decisions, and downstream development.
Our custom antibody programs are typically structured around development periods of approximately 40 to 60 days, depending on the project and scientific requirements.
Speed, however, should not be treated as separate from quality.
A rapidly generated antibody that fails in the intended application does not solve the development problem.
Our emphasis is therefore on combining efficient project execution with application-specific screening and scientific evaluation.
Custom antibody development works best when the development team understands the end goal.
We encourage scientific discussion at the beginning of a project so screening strategy, assay needs, target biology, and potential technical risks can be considered before development begins.
This consultative approach is especially valuable for anti-idiotype programs because seemingly small differences in desired assay behavior can change which antibodies are most useful.
Princeton pharmaceutical teams can work with us to define these requirements before a development path is finalized.
Precision Antibody performs its antibody development work at our Columbia, Maryland facility.
For New Jersey pharmaceutical and biotechnology organizations, this provides access to a specialized USA based development partner while maintaining clear geographic transparency.
We do not claim a Princeton or New Jersey laboratory.
Instead, we support Princeton-area programs through our established antibody development operation in Maryland.
Confidentiality arrangements are available for proprietary programs, and customer ownership of developed clones provides additional control over important research assets.
Princeton’s scientific community sits within a broader central New Jersey environment shaped by pharmaceutical research, biotechnology, biomedical engineering, translational science, and life sciences entrepreneurship.
That environment creates diverse antibody development needs.
A therapeutic antibody program may require multiple specialized reagents over its lifecycle.
Early research may involve target-specific monoclonal antibody development.
A therapeutic discovery program may require fully human antibody candidates.
Preclinical progression may create a need for PK reagents or anti-idiotype antibodies.
Bioanalytical teams may then need capture and detection pairs with clearly defined binding behavior.
These are related but distinct technical challenges.
Precision Antibody can support multiple points within that continuum while keeping antibody performance tied to the intended use.
We work with organizations regardless of whether they are located next to our facility.
For Princeton, Mercer County, and central New Jersey teams, project collaboration can be organized around defined milestones, scientific discussions, sample requirements, data review, and delivery of selected clones or antibody materials.
The important question is not whether the development laboratory shares the same ZIP code.
The important question is whether the development team has the scientific experience, screening capabilities, characterization tools, and project structure required for the program.
Yes. Precision Antibody can support pharmaceutical, biotechnology, research, and related organizations in Princeton and throughout central New Jersey.
Our antibody development facility is located in Columbia, Maryland. We serve Princeton teams from that USA based facility and do not claim a physical laboratory or office in Princeton.
An anti-idiotype antibody recognizes unique structural features of another antibody.
In pharmaceutical development, anti-idiotype antibodies are commonly generated against therapeutic monoclonal antibodies and may be used as highly specific reagents in pharmacokinetic and bioanalytical assays.
Their exact use depends on which region of the therapeutic antibody they recognize and what the assay is intended to measure.
An anti-paratope antibody recognizes the antigen binding region of another antibody. An anti-idiotope antibody may recognize a unique region outside the immediate antigen binding site.
This difference can affect whether the anti-ID reagent recognizes therapeutic antibody when its target antigen is present.
That distinction is important when designing assays for different drug populations.
Anti-idiotype antibodies are commonly used as critical reagents in therapeutic antibody bioanalysis, including pharmacokinetic applications.
They can also be relevant within broader immunogenicity and ADA program workflows, depending on assay design and the specific reagent requirements.
The appropriate antibody strategy should be based on the analytical objective rather than assuming the same reagent configuration is suitable for every PK or ADA assay.
Precision Antibody typically develops custom antibodies within approximately 40 to 60 days, although the exact timeline depends on the target, immune response, screening requirements, characterization needs, and project design.
Some projects may require additional work if more extensive testing or specialized characterization is needed.
Antibody pairs can be evaluated based on whether two antibodies recognize compatible epitopes and function together effectively in the intended assay format.
Epitope binning, binding measurements, matrix testing, and application-specific screening can help identify useful capture and detection combinations.
Pair selection should be based on assay performance rather than binding data alone.
A fully human monoclonal antibody contains human immunoglobulin sequences rather than beginning as a conventional mouse antibody that must later be humanized.
Precision Antibody uses Trans Chromosomics mice as part of its fully human antibody development capability.
These animals can generate antigen-specific fully human IgG through an immune response following immunization.
The process begins with target and immunogen planning, followed by immunization of an appropriate transgenic mouse platform.
After an immune response develops, antibody producing cells can be used for hybridoma generation, cloning, screening, and candidate selection.
Selected antibodies may then undergo characterization, sequencing, production, or further functional evaluation depending on the program.
A fully human antibody is generated with human immunoglobulin sequences from the outset.
A humanized antibody typically begins with a nonhuman antibody whose important antigen binding regions are incorporated into a largely human antibody framework through molecular engineering.
Both approaches can be useful. The appropriate development route depends on the therapeutic strategy, target, available starting material, and program requirements.
Precision Antibody provides customers with ownership of developed clones according to the terms of the project.
This can be particularly important for pharmaceutical and biotechnology teams that need control over proprietary research reagents, therapeutic program assets, or downstream development materials.
Our antibody development work is performed at our facility in Columbia, Maryland.
We serve pharmaceutical, biotechnology, diagnostic, academic, and research organizations in Princeton, New Jersey and other locations from that facility.
A productive antibody development project begins with a clear understanding of what the final reagent needs to accomplish.
For a PK program, that may mean determining whether free drug, total drug, or another therapeutic antibody population must be measured.
For an anti-idiotype program, it may mean deciding whether anti-paratope, anti-idiotope, or paired reagents best support the assay.
For therapeutic discovery, it may mean generating fully human monoclonal antibody candidates and selecting clones based on functional and binding characteristics.
Our role is to help translate those requirements into a development strategy built around the intended application.
Precision Antibody supports Princeton pharmaceutical and biotechnology teams with custom antibody development, anti-idiotype programs, fully human monoclonal antibody development, antibody characterization, application-specific screening, and related downstream services from our Columbia, Maryland facility.
Whether the challenge involves PK assay reagents, therapeutic antibody detection, fully human candidate generation, antibody pairing, matrix performance, or another specialized development requirement, we approach the project by starting with the scientific objective and working backward to the development and screening strategy needed to support it.
